Current hepatitis C therapy

Česká verzia

Authors: Petr Husa; Svatava Snopková; Petr Husa ml.
Authors place of work: Klinika infekčních chorob LF MU a FN Brno
Published in the journal: Čas. Lék. čes. 2022; 161: 90-93
Category: Review Article

Summary

Hepatitis C virus (HCV) infection is still a major cause of chronic liver diseases, with approximately 71 million chronically infected persons worldwide. People who inject drugs currently or in the past (PWID), mostly intravenously, are the main risk group among HCV chronically infected persons. The efficacy of therapy with direct acting antivirals (DAA) is almost 100 %. Currently, the main mission is to diagnose HCV infection in the most possible number of infected persons; it is in collision with poor adherence of PWID in particular.

Keywords:

chronic hepatitis C – HCV elimination – direct acting antivirals (DAA)

Zdroje

European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. CPG HCV. J Hepatol 2020; 73(5): 1170–1218.
World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version 2019. WHO, 2019. Dostupné na: www.who.int/news-room/fact-sheets/detail/hepatitis-c
Selvapatt N, Ward T, Harrison L et al. The cost impact of outreach testing and treatment for hepatitis C in an urban drug treatment unit. Liver Int Off J Int Assoc Study Liver 2017; 37(3): 345–353.
Kim H, Guerrero R, Reader SW et al. Low yield of hepatitis C infection in an outreach screening program in Harris County, Texas. Open Forum Infect Dis 2020; 7(7): ofaa19.
Husa P ml., Husa P. Význam terénního testování v eliminaci hepatitidy C. Klinická mikrobiologie a infekční lékařství 2021; 27(1): 13–17.
Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M et al. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol Hepatol 2018; 41(1): 2–11.
Krekulová L, Řehák V, Strunecký O, Nĕmeček V. Current situation and trends in the hepatitis C virus genotype distribution among injecting drug users in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58(1): 84–89.

Štítky

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

Článek ÚVODEM

Článek EDITORIAL

Článek Liver tests

Článek Diagnostic methods of fatty liver diseases

Článek Liver elastography

Článek Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD – common aspects of pathogenesis

Článek Diagnosis of non-alcoholic fatty liver disease and its active screening in risk groups

Článek An overview of current therapy options of non-alcoholic fatty liver disease

Článek Statins and liver

Článek Alcohol-related liver disease in medical practice

Článek Klinická obezitologie – nejen Základy

Článek Dietary habits in students from the medical faculties